See analyst estimates and all valuation multiples for Genomics & Personalized Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $25.7B | 12.7x | -97.1x | |
| $16.7B | 3.9x | 14.5x | |
| $13.6B | 4.4x | 30.9x | |
| $12.4B | 13.5x | -56.1x | |
| $3.8B | 9.3x | 99.9x | |
| $2.7B | 19.5x | -4.7x | |
| $2.5B | 2.8x | 15.2x | |
| $2.5B | 5.1x | 22.1x | |
| $2.4B | 4.7x | 37.5x | |
| $2.2B | n/a | n/a | |
| $1.7B | 4.5x | -18.6x | |
| $1.2B | 1.9x | -11.1x | |
| $1.1B | 1.9x | 16.7x | |
| $1.1B | 154.8x | -10.4x | |
| $967M | 6.1x | -6.3x | |
| $819M | 1.0x | 27.1x | |
| $793M | 112.5x | -4.5x | |
| $751M | 11.9x | n/a | |
| $713M | 9.5x | -9.1x | |
| $621M | 2.0x | 11.1x | |
| $614M | 1.7x | 20.8x | |
| $555M | n/a | -5.4x | |
| $470M | 122.9x | n/a | |
| $464M | 1.4x | 15.3x | |
| $405M | 1.3x | -26.0x | |
| $327M | n/a | n/a | |
| $327M | n/a | n/a | |
| $320M | 4.4x | -7.8x | |
| $304M | n/a | -59.4x | |
| $291M | 66.0x | n/a | |
| $285M | 5.9x | -4.0x | |
| $240M | 6.2x | -2.1x | |
| $217M | n/a | n/a | |
| $213M | 2.4x | n/a | |
| $180M | n/a | -1.6x | |
| $168M | n/a | -1.1x | |
| $157M | 2.2x | -4.8x | |
| $145M | n/a | -1.6x | |
| $141M | 11.0x | -0.7x | |
| $137M | 61.9x | -6.5x | |
| $113M | 5.0x | -0.6x | |
| $79.3M | 16.7x | -0.8x | |
| $72.5M | 1.7x | n/a | |
| $68.6M | 3.3x | -1.2x | |
| $60.1M | 2.7x | n/a | |
| $57.9M | 5.9x | -0.4x | |
| $50.3M | 19.8x | -1.0x | |
| $23.5M | n/a | -0.3x | |
| $20.5M | 0.7x | -0.2x | |
| $13.0M | n/a | n/a | |
| $9.8M | n/a | n/a | |
| $0.9M | n/a | n/a | |
| -$9.8M | n/a | n/a | |
| -$19.2M | -1.6x | n/a | |
| -$53.2M | -0.6x | n/a | |
| -$70.6M | -2.2x | 0.8x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Genomics & Personalized Medicine